Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 7c
August 9, 2022 4:22 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.55), $0.07 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $4.18 million.
For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.
... More